Tags

Type your tag names separated by a space and hit enter

Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials.
Scand J Infect Dis. 2007; 39(10):858-61.SJ

Abstract

The treatment of melioidosis currently involves the use of antimicrobials such as ceftazidime, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate and doxycycline. Evaluation of other antimicrobials with activity against the organism continues to be pursued, however, as the causative organism, B. pseudomallei, may not always be susceptible to the above antimicrobials. This study aimed to test the susceptibility of Malaysian isolates of B. pseudomallei against imipenem, meropenem, ertapenem, moxifloxacin and azithromycin. 80 previously stocked clinical isolates collected between 1978 and 2003 from the UMMC, Kuala Lumpur were tested for in vitro susceptibility to these antimicrobials using the E-test minimum inhibitory concentration method. 100% of isolates were sensitive to imipenem and meropenem, 97.5% were sensitive to trimethoprim-sulfamethozaxole, 37.5% to moxifloxacin, and only a minority was sensitive to ertapenem (7.5%). Using breakpoints for Staphylococcus and Haemophilus, 5.0%-6.3% of isolates were sensitive to azithromycin. In conclusion, our findings support the in vitro efficacy of imipenem, meropenem and trimethoprim-sulfamethoxazole against B. pseudomallei. Moxifloxacin, ertapenem and azithromycin cannot be recommended for the treatment of melioidosis; however, further studies are needed to test the efficacy of azithromycin in combination with quinolones.

Authors+Show Affiliations

Department of Medical Microbiology, Faculty of Medicine, University of Malaya Kuala Lumpur, Malaysia. rinakarunakaran@yahoo.comNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17852912

Citation

Karunakaran, Rina, and Savithri D. Puthucheary. "Burkholderia Pseudomallei: in Vitro Susceptibility to some New and Old Antimicrobials." Scandinavian Journal of Infectious Diseases, vol. 39, no. 10, 2007, pp. 858-61.
Karunakaran R, Puthucheary SD. Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials. Scand J Infect Dis. 2007;39(10):858-61.
Karunakaran, R., & Puthucheary, S. D. (2007). Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials. Scandinavian Journal of Infectious Diseases, 39(10), 858-61.
Karunakaran R, Puthucheary SD. Burkholderia Pseudomallei: in Vitro Susceptibility to some New and Old Antimicrobials. Scand J Infect Dis. 2007;39(10):858-61. PubMed PMID: 17852912.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials. AU - Karunakaran,Rina, AU - Puthucheary,Savithri D, PY - 2007/9/14/pubmed PY - 2007/12/28/medline PY - 2007/9/14/entrez SP - 858 EP - 61 JF - Scandinavian journal of infectious diseases JO - Scand J Infect Dis VL - 39 IS - 10 N2 - The treatment of melioidosis currently involves the use of antimicrobials such as ceftazidime, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate and doxycycline. Evaluation of other antimicrobials with activity against the organism continues to be pursued, however, as the causative organism, B. pseudomallei, may not always be susceptible to the above antimicrobials. This study aimed to test the susceptibility of Malaysian isolates of B. pseudomallei against imipenem, meropenem, ertapenem, moxifloxacin and azithromycin. 80 previously stocked clinical isolates collected between 1978 and 2003 from the UMMC, Kuala Lumpur were tested for in vitro susceptibility to these antimicrobials using the E-test minimum inhibitory concentration method. 100% of isolates were sensitive to imipenem and meropenem, 97.5% were sensitive to trimethoprim-sulfamethozaxole, 37.5% to moxifloxacin, and only a minority was sensitive to ertapenem (7.5%). Using breakpoints for Staphylococcus and Haemophilus, 5.0%-6.3% of isolates were sensitive to azithromycin. In conclusion, our findings support the in vitro efficacy of imipenem, meropenem and trimethoprim-sulfamethoxazole against B. pseudomallei. Moxifloxacin, ertapenem and azithromycin cannot be recommended for the treatment of melioidosis; however, further studies are needed to test the efficacy of azithromycin in combination with quinolones. SN - 0036-5548 UR - https://www.unboundmedicine.com/medline/citation/17852912/Burkholderia_pseudomallei:_in_vitro_susceptibility_to_some_new_and_old_antimicrobials_ L2 - https://www.tandfonline.com/doi/full/10.1080/00365540701402988 DB - PRIME DP - Unbound Medicine ER -